Michael Tomsicek's most recent trade in Acrivon Therapeutics Inc was a trade of 20,275 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics Inc | Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 20,275 | 20,275 | - | - | Stock Option (Right to Buy) | |
| Milestone Pharmaceuticals Inc | Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Milestone Pharmaceuticals Inc | Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Acrivon Therapeutics Inc | Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,275 | 20,275 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 35,235 | 35,235 | - | - | Stock Option (Right to Buy) | |
| Milestone Pharmaceuticals Inc | Michael J. Tomsicek | Director | Purchase of securities on an exchange or from another person at price $ 5.32 per share. | 19 Oct 2022 | 15,000 | 15,000 (0%) | 0% | 5.3 | 79,800 | Common Shares |
| Milestone Pharmaceuticals Inc | Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| CRISPR Therapeutics AG | Michael J. Tomsicek | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 25,000 | 131,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Michael J. Tomsicek | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.75 per share. | 06 Aug 2021 | 25,000 | 26,891 (0%) | 0% | 17.8 | 443,750 | Common Shares |
| CRISPR Therapeutics AG | Michael J. Tomsicek | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 138.22 per share. | 06 Aug 2021 | 19,011 | 7,880 (0%) | 0% | 138.2 | 2,627,700 | Common Shares |
| CRISPR Therapeutics AG | Michael J. Tomsicek | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 139.46 per share. | 06 Aug 2021 | 5,989 | 1,891 (0%) | 0% | 139.5 | 835,226 | Common Shares |
| Milestone Pharmaceuticals Inc | Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| CRISPR Therapeutics AG | Michael J. Tomsicek | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 25,360 | 25,360 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Michael J. Tomsicek | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 9,000 | 9,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Michael J. Tomsicek | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 2,833 | 3,243 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Michael J. Tomsicek | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.15 per share. | 10 Mar 2021 | 1,352 | 1,891 (0%) | 0% | 124.2 | 167,851 | Common Shares |
| CRISPR Therapeutics AG | Michael Tomsicek | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2020 | 11,666 | 11,666 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Michael Tomsicek | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.75 per share. | 01 Sep 2020 | 12,000 | 12,410 (0%) | 0% | 17.8 | 213,000 | Common Shares |
| CRISPR Therapeutics AG | Michael Tomsicek | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 12,000 | 156,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Michael Tomsicek | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 92.23 per share. | 01 Sep 2020 | 6,400 | 3,210 (0%) | 0% | 92.2 | 590,272 | Common Shares |
| CRISPR Therapeutics AG | Michael Tomsicek | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 91.39 per share. | 01 Sep 2020 | 2,800 | 9,610 (0%) | 0% | 91.4 | 255,892 | Common Shares |
| CRISPR Therapeutics AG | Michael Tomsicek | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 93.18 per share. | 01 Sep 2020 | 2,800 | 410 (0%) | 0% | 93.2 | 260,904 | Common Shares |
| CRISPR Therapeutics AG | Michael Tomsicek | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 12,000 | 168,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Michael Tomsicek | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.75 per share. | 03 Aug 2020 | 12,000 | 12,410 (0%) | 0% | 17.8 | 213,000 | Common Shares |
| CRISPR Therapeutics AG | Michael Tomsicek | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 86.25 per share. | 03 Aug 2020 | 6,552 | 5,858 (0%) | 0% | 86.3 | 565,128 | Common Shares |
| CRISPR Therapeutics AG | Michael Tomsicek | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 87.33 per share. | 03 Aug 2020 | 5,448 | 410 (0%) | 0% | 87.3 | 475,790 | Common Shares |